Table 2.
Baseline characteristics of the study population.
| All patients (n=116) | Completed (n=98) | Did not complete (n=18) | p | |
|---|---|---|---|---|
| Female/male, n | 21/95 | 16/82 | 5/13 | 0.246 |
| Age, years | 62.6±8.9 | 63.0±8.5 | 60.17±11.2 | 0.154 |
| BMI, kg/m2 | 27.5±3.3 | 27.7±3.2 | 26.4±3.9 | 0.448 |
| MVPA, min/week | 239±209 | 230±198 | 286±264 | 0.148 |
| Diagnosis, % | ||||
| CAD | 88.8 | 88.8 | 88.9 | 0.989 |
| Heart failure | 13.8 | 14.3 | 11.1 | 0.720 |
| Valve disease | 5.2 | 4.1 | 11.1 | 0.216 |
| PAD | 3.4 | 3.1 | 5.6 | 0.594 |
| Implantable device | 12.1 | 13.3 | 5.6 | 0.356 |
| LVEF (%) | 52.8±10.7 | 52.9±10.8 | 52.5±10.0 | 0.710 |
| Risk factors, % | ||||
| Family history of CVD | 41.7 | 41.8 | 41.2 | 0.959 |
| Hypertension | 58.6 | 60.2 | 52.9 | 0.574 |
| Type 2 diabetes | 18.1 | 17.9 | 22.2 | 0.572 |
| Dyslipidemia | 37.9 | 37.8 | 38.9 | 0.789 |
| Ex-smoker | 51.7 | 55.4 | 35.3 | 0.089 |
| Smoker | 12.9 | 14.3 | 5.9 | 0.310 |
| Overweight (BMI >25 kg/m2) | 74.7 | 78.3 | 50.0 | 0.055 |
| Medications, % | ||||
| Beta-blockers | 79.3 | 79.6 | 66.7 | 0.560 |
| Statins | 80.2 | 79.6 | 81.3 | 0.978 |
| Diuretics | 28.4 | 31.6 | 13.3 | 0.135 |
| ACE inhibitors | 51.7 | 52.0 | 43.8 | 0.462 |
| Antiplatelets | 38.8 | 38.8 | 44.4 | 0.433 |
| Aspirin | 78.4 | 75.5 | 83.3 | 0.127 |
ACE: angiotensin-converting enzyme; BMI: body mass index; CAD: coronary artery disease; CVD: cardiovascular disease; LVEF: left ventricular ejection fraction; MVPA: moderate to vigorous physical activity; PAD: peripheral arterial disease.
Data are mean ± SD.